Giuseppe Curigliano mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Surgery. His Pathology research extends to the thematically linked field of Internal medicine. His biological study spans a wide range of topics, including Clinical endpoint and Adverse effect.
His Oncology research is multidisciplinary, incorporating perspectives in Pembrolizumab, Clinical trial, Chemotherapy, Phases of clinical research and Triple-negative breast cancer. His Cancer research is multidisciplinary, incorporating elements of Immunology, Intensive care medicine, Carcinoma, Melanoma and Disease. His work deals with themes such as Breast reconstruction, Adjuvant, Mastectomy and Hazard ratio, which intersect with Surgery.
Giuseppe Curigliano mostly deals with Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Giuseppe Curigliano combines topics linked to Surgery with his work on Internal medicine. His research in Surgery is mostly concerned with Radiation therapy.
The study incorporates disciplines such as Randomized controlled trial, Disease, Hazard ratio, Triple-negative breast cancer and Immunotherapy in addition to Oncology. His study in Breast cancer is interdisciplinary in nature, drawing from both Adjuvant, Immunology and Cancer research. His Cancer research incorporates themes from Immune system, Antigen and Intensive care medicine.
Internal medicine, Oncology, Breast cancer, Cancer and Clinical trial are his primary areas of study. His work in the fields of Chemotherapy, Metastatic breast cancer and Immunotherapy overlaps with other areas such as In patient. His research integrates issues of Precision medicine, Trastuzumab, Randomized controlled trial, Disease and Hazard ratio in his study of Oncology.
His Trastuzumab study integrates concerns from other disciplines, such as Biosimilar and Capecitabine. His studies in Breast cancer integrate themes in fields like Cancer research, Tumor-infiltrating lymphocytes and Family medicine. His Cancer research includes elements of Immune system and Intensive care medicine.
Giuseppe Curigliano focuses on Internal medicine, Oncology, Cancer, Breast cancer and Disease. Giuseppe Curigliano interconnects Clinical trial, Trastuzumab, Metastatic breast cancer, Biomarker and Immunotherapy in the investigation of issues within Oncology. The concepts of his Clinical trial study are interwoven with issues in Pathological, Tolerability, Adverse effect, Triple-negative breast cancer and Drug resistance.
He has included themes like Cancer research, Risk of infection and Intensive care medicine in his Cancer study. His Breast cancer research includes elements of Chemotherapy, Tumor-infiltrating lymphocytes, Family medicine, Consensus conference and Anaplastic large-cell lymphoma. His studies examine the connections between Disease and genetics, as well as such issues in Seroconversion, with regards to Immunoglobulin G, Interquartile range and Observational study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Daniela Cardinale;Alessandro Colombo;Giulia Bacchiani;Ines Tedeschi.
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
G. Curigliano;D. Cardinale;T. Suter;G. Plataniotis.
Annals of Oncology (2012)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment
Marco Colleoni;Giuseppe Viale;David Zahrieh;Giancarlo Pruneri.
Clinical Cancer Research (2004)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale.
Annals of Oncology (2014)
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.
Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell.
Advances in Anatomic Pathology (2017)
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Giuseppe Curigliano;Daniela Cardinale;Susan Dent;Carmen Criscitiello.
CA: A Cancer Journal for Clinicians (2016)
Annals of Oncology
(Impact Factor: 51.769)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: